Scribe Therapeutics Inc. (SCTX)

Scribe Therapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Scribe Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	36.28	51.17	27.41
Revenue Growth (YoY)	-	86.68%	-
Gross Profit	36.28	51.17	27.41
Selling, General & Admin	-	16.45	13.16
Research & Development	-	60.8	57.08
Operating Expenses	-	77.24	70.24
Operating Income	-32.94	-26.07	-42.83
Interest Expense (Income)	-0.39	-0.93	-3.77
Other Expense (Income)	4.43	-1.53	-1.5
Pretax Income	-36.99	-23.61	-37.56
Income Tax	-1.26	-1.8	10.23
Net Income	-35.73	-21.81	-47.79
Free Cash Flow	-39.94	-46.48	-46.58
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-90.79%	-50.94%	-156.24%
Profit Margin	-98.48%	-42.61%	-174.32%
Free Cash Flow Margin	-110.09%	-90.83%	-169.93%
EBITDA	-33.5	-20.64	-37.81
EBITDA Margin	-92.34%	-40.33%	-137.94%
Depreciation & Amortization	3.87	3.91	3.52
EBIT	-37.37	-24.54	-41.33
EBIT Margin	-103.01%	-47.96%	-150.78%